OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
The new line will add capacity to Catalent’s pipeline of clinical programs and commercial launches at the site.
Catalent announced on Sept. 2, 2020 that it is investing $50 million to install a high-speed vial filling line at its Bloomington, IN, facility.
Expected to be operational in April 2021, the new line will add capacity to Catalent’s pipeline of clinical programs and commercial launches at the site, a company press release said. It will also provide capacity to produce up to 80 million vials annually under barrier isolator technology and a peristaltic pump filling mechanism.
This is the third major investment into the Bloomington facility in two years and, by 2021, the site will offer high-speed filling capacity across three vial lines, two syringe lines, and a flexible line capable of filling vials, syringes, or cartridges, the press release said.
“The industry has seen an increased demand for vial filling of biologic drugs, which has been compounded by the accelerated development of vaccine and therapeutic candidates to address the COVID-19 pandemic,” said Mike Riley, region president, Biologics, North America, in the press release. “Catalent’s continued investment in this capacity will allow us to remain flexible and continue to support the growth of our customers’ programs.”